SAN DIEGO--(BUSINESS WIRE)--Jun. 23, 2009--
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company
developing and commercializing products targeting the extracellular
matrix, today announced that it has raised gross proceeds of $40 million
through the public offering of 6,150,000 million newly issued shares of
its common stock. The public offering price of $6.50 per share
represents a discount of 11.6% relative to the average closing share
price during the five trading days preceding the public offering. Net
proceeds, after underwriting discounts and commissions and expenses,
will be approximately $38.2 million. Jefferies & Company, Inc. is the
sole underwriter for this offering. The offering is expected to close on
June 26, 2009, subject to customary closing conditions.
The securities described above are being offered by Halozyme pursuant to
a shelf registration statement previously filed and declared effective
by the Securities and Exchange Commission on January 8, 2009. A
prospectus supplement related to the offering has been filed with the
SEC and is available on the SEC’s Web site at http://www.sec.gov.
Copies of the prospectus supplement relating to these securities may be
obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus
Department, 520 Madison Avenue, New York, NY, 10022 and at (888)
449-2342. This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing
products targeting the extracellular matrix for the endocrinology,
oncology, dermatology and drug delivery markets. The company's portfolio
of products and product candidates is based on intellectual property
covering the family of human enzymes known as hyaluronidases and
additional enzymes that target the extracellular matrix. Halozyme’s
Enhanze™ Technology is a novel drug delivery platform
designed to increase the absorption and dispersion of biologics. The
company has key partnerships with Roche to apply Enhanze Technology to
Roche’s biological therapeutics for up to 13 targets and with Baxter
BioScience to apply Enhanze Technology to Baxter’s biological
therapeutic compound, GAMMAGARD LIQUID™. The product
candidates in Halozyme’s research pipeline target multiple areas of
significant unmet medical need. For more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above
include forward-looking statements (including, without
limitation, statements concerning the public offering) that involve risk
and uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. The forward-looking
statements are also identified through use of the words "believe,"
"enable," "may," "will," "could," "intends," "estimate," "anticipate,"
"plan," "predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results could
differ materially from the expectations contained in forward-looking
statements as a result of several factors, including regulatory approval
requirements and competitive conditions. These and other factors that
may result in differences are discussed in greater detail in the
company's reports on Forms 10-K, 10-Q, and other filings with the
Securities and Exchange Commission.
Source: Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc.
Robert H. Uhl